Emerging drugs for the treatment of primary sclerosing cholangitis

A pilot integrative analysis of colonic gene expression, gut microbiota and immune infiltration in primary sclerosing cholangitis-inflammatory bowel disease: association of disease with bile acid pathways

(2020) Mohammed Nabil Quraishi et al.   Journal of Crohns & Colitis

Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Diseases, Based on Sex, Race, and Age

(2020) Palak J. Trivedi et al.   GASTROENTEROLOGY

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

(2020) Kris V. Kowdley et al.   JOURNAL OF HEPATOLOGY

Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis

(2020) Ahmad Hassan Ali et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial

(2020) Elsemieke de Vries et al.   GASTROENTEROLOGY

CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2–/– mouse model.

(2020) Neta Barashi et al.   JOURNAL OF HEPATOLOGY

Cellular therapies for the treatment of immune-mediated GI and liver disease

(2020) Sheeba Khan et al.   BRITISH MEDICAL BULLETIN

Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice

(2020) Roberta Angioni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC

(2019) Michael Trauner et al.   HEPATOLOGY

Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis

(2019) Alexander Dao et al.   INFLAMMATORY BOWEL DISEASES

Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis

(2019) Jessica R. Allegretti et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis

(2019) Malte Rühlemann et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis

(2019) Michael Huw Chapman et al.   GUT

Direct and Indirect Effects of FGF15 and FGF19 on Liver Fibrosis Development

(2019) J D Schumacher et al.   HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

(2018) B. Christensen et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease

(2018) C. S. Tse et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis

(2018) P. J. Trivedi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines

(2018) Gideon M Hirschfield et al.   GUT

Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

(2018) Cyriel Y. Ponsioen et al.   HEPATOLOGY

Point prevalence survey of carbapenemase-producing Enterobacteriaceae (CPE) and vancomycin-resistant enterococci (VRE) in adult inpatients in a University teaching hospital in the United Kingdom

(2018) Hayley J. Wilson et al.   JOURNAL OF HOSPITAL INFECTION

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

(2018) Christophe Corpechot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis–ulcerative colitis

(2018) Li-Zsa Tan et al.   GUT

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease

(2018) Andrew J. Muir et al.   HEPATOLOGY

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience

(2018) Sara Lemoinne et al.   Clinics and Research in Hepatology and Gastroenterology

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis

(2018) William J. Sandborn et al.   GASTROENTEROLOGY

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System

(2018) E C Goode et al.   HEPATOLOGY

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial

(2018) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

(2017) Tobias J. Weismüller et al.   GASTROENTEROLOGY

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner

(2017) Palak J Trivedi et al.   GUT

Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis

(2017) David N. Assis et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

(2017) Peter Fickert et al.   JOURNAL OF HEPATOLOGY

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study

(2017) Vinod S Hegade et al.   LANCET

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol

(2017) Katherine Arndtz et al.   BMJ Open

The features of mucosa-associated microbiota in primary sclerosing cholangitis

(2016) J. Torres et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD

(2016) Aliya F Gulamhusein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The gut-adherent microbiota of PSC–IBD is distinct to that of IBD

(2016) Mohammed Nabil Quraishi et al.   GUT

Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD

(2016) João Sabino et al.   GUT

The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls

(2016) Martin Kummen et al.   GUT

Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity

(2016) Palak J. Trivedi et al.   JOURNAL OF AUTOIMMUNITY

A triple blinded, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of oral vancomycin in primary sclerosing cholangitis: a pilot study

(2016)   Journal of Gastrointestinal and Liver Diseases

Gut–liver immunity

(2016) Palak J. Trivedi et al.   JOURNAL OF HEPATOLOGY

Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value

(2016) Elisabeth M. G. de Vries et al.   LIVER INTERNATIONAL

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

ACG Clinical Guideline: Primary Sclerosing Cholangitis

(2015) Keith D Lindor et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis

(2015) Naoki Yoshimura et al.   GASTROENTEROLOGY

Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis

(2015) Zhen-Wei Peng et al.   HEPATOLOGY

Fibrates and cholestasis

(2015) Nisanne S. Ghonem et al.   HEPATOLOGY

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

(2015) Cyriel Y. Ponsioen et al.   HEPATOLOGY

Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis

(2015) D. Kevans et al.   Journal of Crohns & Colitis

Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis

(2015) Suguru Mizuno et al.   Journal of Hepato-Biliary-Pancreatic Sciences

New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond

(2015) Ulrich Beuers et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of primary biliary cirrhosis

(2015) Palak J Trivedi et al.   Expert Review of Clinical Pharmacology

Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis

(2014) Chris J. Weston et al.   JOURNAL OF CLINICAL INVESTIGATION

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study

(2013) J. H. Tabibian et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

(2013) Kirsten Boonstra et al.   HEPATOLOGY

Mucosal immunity in liver autoimmunity: A comprehensive review

(2013) Palak J. Trivedi et al.   JOURNAL OF AUTOIMMUNITY

Primary sclerosing cholangitis

(2013) Gideon M Hirschfield et al.   LANCET

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

(2012) Akira Honda et al.   HEPATOLOGY

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study

(2012) K.R. Herrlinger et al.   Journal of Crohns & Colitis

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review

(2012) Kirsten Boonstra et al.   JOURNAL OF HEPATOLOGY

Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis

(2011) E. L. Culver et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

(2011) M. H. Imam et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis

(2011) John E Eaton et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Bezafibrate for the treatment of primary sclerosing cholangitis

(2010) Suguru Mizuno et al.   JOURNAL OF GASTROENTEROLOGY

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice

(2009) Emina Halilbasic et al.   HEPATOLOGY

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

(2009) Keith D. Lindor et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

(2009)   JOURNAL OF HEPATOLOGY

Long-term Treatment of Primary Sclerosing Cholangitis in Children With Oral Vancomycin: An Immunomodulating Antibiotic

(2009) Yinka K Davies et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Inhibition of Integrin αvβ6 on Cholangiocytes Blocks Transforming Growth Factor-β Activation and Retards Biliary Fibrosis Progression

(2008) Eleonora Patsenker et al.   GASTROENTEROLOGY

A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis

(2008) Daan W. Hommes et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY